ArticleImmuno-oncology technology2026
The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma.
Article in Immuno-oncology technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myxofibrosarcoma (MFS) is a subtype of soft-tissue sarcoma for which local treatment includes neoadjuvant radiotherapy (nRT) followed by surgery. The impact of nRT on the MFS tumor immune microenvironment remains unexplored. Materials and methods: Paired pre-nRT biopsy and post-nRT surgery samples from 31 MFS patients were retrospectively collected. The intratumoral density of T cells, cytotoxic T cells, regulatory T cells, helper T cells, B cells and natural killer (NK) cells and expression of programmed death-ligand 1 were quantified using multiplex immunohistochemistry (mIHC). mIHC marker densities were compared between pre- and post-nRT samples, and their associations with clinicopathological characteristics and patient outcomes were assessed. Results: There was substantial interpatient heterogeneity in mIHC marker densities, both pre- and post-nRT. A significant reduction in cytotoxic T cell {205 [interquartile range (IQR) 674] pre-nRT versus 58 (IQR 205) post-nRT, Conclusions: Conventional nRT is associated with reduced cytotoxic and helper T cell infiltration and increased presence of NK cells in MFS. These results suggest that conventional nRT reduces inflammatory aspects of MFS tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.